The present invention relates to a polymeric human growth hormone prodrug and dry, liquid and reconstituted pharmaceutical formulations comprising said prodrug. It furthermore relates to their use as medicaments for the treatment of diseases which can be treated with growth hormone and to methods of treatment. It also relates to methods of application of such polymeric human growth hormone prodrug or pharmaceutical formulation.

Provided is a thermoplastic resin composition which has excellent heat resistance, mechanical characteristics, and adhesion properties with respect to a reinforcing fiber base material, which is a different kind of material, and from which a molded article particularly having excellent rigidity at a high temperature is obtained. A thermoplastic resin composition is provided, which includes: a phenoxy resin (A) having a hydroxy group and/or an epoxy group at a polymer chain terminal; and a polyamide resin (B), wherein a proportion of the phenoxy resin (A) is 50 to 90 mass % and a proportion of the polyamide resin (B) is 10 to 50 mass % relative to a total amount of 100 mass % of the phenoxy resin (A) and the polyamide resin (B), and a tensile modulus retention rate [Equation (i) below] of a dumbbell test piece (JIS K 7139, Type A1), and a molded article manufactured therefrom is also provided.

A polyoxyalkylene polymer including a main chain structure of a polyoxyalkylene and terminal structures bonded to ends of the main chain structure is provided. The terminal structures include a hydrolyzable silyl group and further include a terminal olefin group and/or an internal olefin group. The total number of the hydrolyzable silyl, terminal olefin, and internal olefin groups is more than 1.0 on average per terminal structure, and the ratio of the number of moles of the hydrolyzable silyl groups to the total number of moles of the hydrolyzable silyl, terminal olefin, and internal olefin groups is from 0.3 to 0.7.

Reaction products of an optionally alkoxylated alcohol, a polyalkylene alcohol and a linker can be used in various applications such as defoamers. Methods of making the reaction products and defoamer compositions including the reaction products, and methods of using the reaction products to reduce or prevent foam in a composition are also disclosed. The reaction products can be used with an organic solvent or without an organic solvent to provide low VOC compositions.

The present invention relates to a polymeric human growth hormone prodrug and dry, liquid and reconstituted pharmaceutical formulation comprising said prodrug. It furthermore relates to their use as medicaments for the treatment of diseases which can be treated with growth hormone and to methods of treatment. It also relates to methods of application of such polymeric human growth hormone prodrug or pharmaceutical formulation.

A one component epoxy adhesive composition is comprised of an epoxy resin, a polyurethane based toughener, an epoxy capped toughener comprised of a polymer backbone capped with an epoxy, wherein the polymer backbone is at least partially immiscible in the epoxy resin; and an epoxy curing agent. The one component adhesive composition may have improved impact resistance at low temperatures, such as 40 C. or less. The epoxy based toughener may be formed by reacting the hydroxyls of a polyol with a stoichiometric excess of cyclic anhydride to form a carboxylic acid capped polymer. The carboxylic acid capped polymer is then reacted with a stoichiometric excess of an epoxy resin having at least two epoxides to form the epoxy capped toughener having epoxide end groups.

The present invention relates to a polymeric human growth hormone prodrug and dry, liquid and reconstituted pharmaceutical formulation comprising said prodrug. It furthermore relates to their use as medicaments for the treatment of diseases which can be treated with growth hormone and to methods of treatment. It also relates to methods of application of such polymeric human growth hormone prodrug or pharmaceutical formulation.

Polymeric barriers for organic light emitting diodes are formed in-situ by encapsulation or polymerization. Encapsulation with melamine-cyanurate is performed using sublimation reaction technique. An encapsulation technique involves curing a layer of resin made by mixing a polyaza aryl compound, such as melamine, melam, or melem, with a cyanuryl triglycidyl ether. Another encapsulation technique involves curing a layer of resin made by mixing the polyaza aryl aromatic compound in 2,4,6-tricyanatophenyl glycidyl ether or tetracyanatobenzene applied to an organic light emitting diode. Photo catalytic curing of the coating may be achieved in the presence of catalysts such as titanium IV oxide acetylacetonate.

The present invention relates to a polymeric human growth hormone prodrug and dry, liquid and reconstituted pharmaceutical formulations comprising said prodrug. It furthermore relates to their use as medicaments for the treatment of diseases which can be treated with growth hormone and to methods of treatment. It also relates to methods of application of such polymeric human growth hormone prodrug or pharmaceutical formulation.

Reaction products of an optionally alkoxylated alcohol, a polyalkylene alcohol and a linker can be used in various applications such as defoamers. Methods of making the reaction products and defoamer compositions including the reaction products, and methods of using the reaction products to reduce or prevent foam in a composition are also disclosed. The reaction products can be used with an organic solvent or without an organic solvent to provide low VOC compositions.